OCRA’s Ovarian Cycle Tampa event was in the news this week, shining a well-deserved light on the event’s riders and organizers, and what inspires them to participate in OCRA’s signature fundraising event. The fitness and fundraising event took place on September 30th at CycleBar in Tampa, on the final day of Ovarian Cancer Awareness Month. … Continued
OCRA Announces Game-Changing Initiatives This month, OCRA announced a trio of initiatives that carry profound implications for ovarian cancer and related research and patient support: OCRA will expand its mission to include related gynecologic cancers, will create the first comprehensive ovarian and endometrial cancer registry, and will initiate a groundbreaking international data commons. Audra Moran, President and CEO of … Continued
New York, NY, September 26, 2023 — As Ovarian Cancer Awareness Month draws to a close, Ovarian Cancer Research Alliance (OCRA) is announcing a trio of initiatives that carry profound implications for ovarian cancer and related research and patient support: OCRA will expand its mission to include related gynecologic cancers, will create the first comprehensive ovarian and endometrial cancer … Continued
Snap Summary: Research co-funded by OCRA found that foregoing genetic counseling before and after genetic testing does not negatively impact individuals who do not have a pathogenic mutation. Studies have shown that people who might have a hereditary cancer risk often do not get tested. This makes it important to identify needless barriers that may … Continued
Snap Summary: An OCRA-funded study sought to understand why certain ovarian cancer cells resist olaparib treatment, and discovered that introducing a second drug (mifepristone) while targeting certain cells (polyploid giant cancer cells) may offer a solution. In a study published in the journal Science Advances, researchers at MD Anderson Cancer Center set their sights on … Continued
OCRA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. We’re proud to receive the highest possible rating from Charity Navigator, as it reflects our deep commitment to ending ovarian cancer and helping all those affected by a gynecologic cancer. A 4-star rating means that … Continued
OCRA’s important message urging genetic testing and consideration of prophylactic action to reduce risk of ovarian cancer has received a significant boost from various media outlets, including Yahoo! Finance and AP News. OCRA is grateful for the opportunity to reach more people with this potentially life-saving information. Read the full press release below. NEW YORK, Sept. … Continued
Special Registration for National Conference Ends Thursday, August 31st OCRA’s Ovarian Cancer National Conference returns virtually on November 1st – 3rd with important updates on research, care, and resources from top experts in the field. Topics will include new treatment developments, symptom management, caregiver concerns, and more, with interactive sessions and opportunities to connect. Regular $75 registration begins … Continued
Jill McGill, professional golfer and champion of the 2022 U.S. Senior Women’s Open, spoke to reporters at this year’s tournament about her personal connection to the ovarian cancer cause. “When you have people that close to you, it really makes you want to make a difference, not only in their lives, but in the future … Continued
As we gear up for Ovarian Cancer Awareness Month, we are turning our attention to two OCRA Heroes who are harnessing the power of everyday technology to garner support for our community and educate others about ovarian cancer via online fundraising campaigns for OCRA. Read on to learn more about their stories and the inspiring … Continued
A recent article from Stat News reports that as the United States continues to face a concerning shortage of vital chemotherapy drugs, ovarian cancer patients are among the hardest hit. According to Stat News, nearly 93% of U.S. cancer centers are reporting shortages of carboplatin, which is the most common first-line treatment for ovarian cancer. … Continued
Dr. Benjamin Bitler of the University of Colorado is a 2022 recipient of OCRA’s Collaborative Research Development Grant. His OCRA-funded project, which is expanding on findings from the Ovarian Cancer Research Group at the University of Colorado, aims to harness cutting-edge molecular profiling and advanced computational analysis in order to predict ovarian cancer recurrence and provide … Continued
Get email updates about research news, action alerts, and ways to join the fight.
